Ireland Relaxes Stance On Biosimilar Switching
But The National Biosimilars Policy Is Still Awaited
The Irish medicines regulator, the HPRA, is proposing to revamp its guidance on biosimilar medicines and to take a more flexible attitude to biosimilar interchangeability and switching. The guidance is expected to feed into a future national biosimilars policy.
